Literature DB >> 24557661

Examining relations between alpha power as well as anterior cingulate cortex-localized theta activity and response to single or dual antidepressant pharmacotherapies.

Natalia Jaworska1, Claude Blondeau2, Pierre Tessier2, Sandhaya Norris2, Wendy Fusee2, Pierre Blier2, Verner Knott2.   

Abstract

Electrocortical indices may be useful in predicting antidepressant response. Greater pretreatment alpha power and high rostral anterior cingulate cortex (rACC) theta activity tend to index a favorable outcome. The predictive utility of alpha power asymmetry has been under-explored. Baseline alpha2 (10.5-13.0 Hz) power/asymmetry, rACC theta2 (6.0-8.0 Hz) activity and early (one week) changes in these measures were assessed in relation to antidepressant response by week 12 to three treatment regimens (escitalopram (ESC) + bupropion (BUP), ESC or BUP) in patients with major depressive disorder (N=51). No treatment differences in response existed at week 12. Overall, treatment responders exhibited high, and non-responders low, frontal baseline alpha2 power. Frontal alpha2 power weakly discriminated responders/non-responders overall while posterior alpha2 power and BA25-localized theta2 activity strongly discriminated ESC responders/non-responders. No associations with alpha2 asymmetry and response emerged. BUP responders exhibited high, and BUP non-responders low, baseline rACC theta2 activity. Greater early decreases in rACC theta2 activity existed in ESC+BUP non-responders versus ESC+BUP responders. BUP responders exhibited greater rACC theta2 activity decreases than ESC responders. These preliminary results indicate that baseline and early changes in alpha2 and rACC theta2 activity associate with response and have implications for tailoring antidepressant treatments.
© The Author(s) 2014.

Entities:  

Keywords:  Depression; alpha2; alpha2 asymmetry; anterior cingulate cortex; bupropion; combination treatment; escitalopram; standardized low-resolution brain electromagnetic tomography (sLORETA); theta2

Mesh:

Substances:

Year:  2014        PMID: 24557661     DOI: 10.1177/0269881114523862

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  4 in total

1.  Prospective testing of a neurophysiologic biomarker for treatment decisions in major depressive disorder: The PRISE-MD trial.

Authors:  Ian A Cook; Aimee M Hunter; Marissa M Caudill; Michelle J Abrams; Andrew F Leuchter
Journal:  J Psychiatr Res       Date:  2020-02-26       Impact factor: 4.791

2.  Leveraging Machine Learning Approaches for Predicting Antidepressant Treatment Response Using Electroencephalography (EEG) and Clinical Data.

Authors:  Natalia Jaworska; Sara de la Salle; Mohamed-Hamza Ibrahim; Pierre Blier; Verner Knott
Journal:  Front Psychiatry       Date:  2019-01-14       Impact factor: 4.157

3.  Resting and TMS-EEG markers of treatment response in major depressive disorder: A systematic review.

Authors:  Rebecca Strafella; Robert Chen; Tarek K Rajji; Daniel M Blumberger; Daphne Voineskos
Journal:  Front Hum Neurosci       Date:  2022-08-04       Impact factor: 3.473

4.  Pre-treatment EEG signal variability is associated with treatment success in depression.

Authors:  Natalia Jaworska; Hongye Wang; Dylan M Smith; Pierre Blier; Verner Knott; Andrea B Protzner
Journal:  Neuroimage Clin       Date:  2017-10-31       Impact factor: 4.881

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.